Drug intelligence / Profile preview

YY-201

Development stage: Phase 1
Lead developer: Yuyu Pharma
Administration: Intravenous, Oral

Overview

YY-201 is an investigational drug developed by Yuyu Pharma, Inc. It is currently undergoing a randomized, open-label, single-dose, two-way crossover clinical trial to assess its pharmacokinetics and safety/tolerability in healthy male volunteers. The study compares YY-201 to Dutasteride and Tadalafil, suggesting a potential therapeutic area related to conditions treated by these comparator drugs, such as benign prostatic hyperplasia or erectile dysfunction, although its specific mechanism of action and primary indication are not disclosed in the provided context.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on YY-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YY-201.